NCT07041008

Brief Summary

This multicentre study, employing a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions that provide care and support services for older adults diagnosed with mild to moderate Alzheimer's disease (AD). The primary aim is to evaluate the effects of two distinct cognitive stimulation modalities (digital vs physical/analogue). The study will assess the impact of individual cognitive stimulation on multiple domains - specifically cognitive function (with an emphasis on memory and executive function), mood, and quality of life - and investigate how institutional and territorial characteristics influence these effects, considering geographical and organisational diversity as potential moderating factors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
514

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

39 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 27, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 13, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2026

Completed
Last Updated

March 25, 2026

Status Verified

June 1, 2025

Enrollment Period

12 days

First QC Date

June 17, 2025

Last Update Submit

March 23, 2026

Conditions

Keywords

older adultscognitive functionmemoryexecutive functiondementiacognitive stimulation therapycognitionneurocognitive disordersindividual therapynon-pharmacological therapymooddepressionanxietyquality of liferandomised controlled trialAlzheimer's disease

Outcome Measures

Primary Outcomes (12)

  • Cognitive functioning assessed through Mini-Mental State Examination (MMSE)

    Cognitive functioning assessed by the Mini-Mental State Examination (MMSE), a gold standard screening tool for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

    Baseline

  • Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)

    Change in cognitive functioning evaluated by the Mini-Mental State Examination (MMSE), a gold standard screening tool for assessing global cognitive function.Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

    12 weeks after the baseline

  • Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)

    Change in cognitive functioning evaluated by the Mini-Mental State Examination (MMSE), a gold standard screening tool for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

    24 weeks after the baseline

  • Cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)

    Evaluates the severity of cognitive deficits in AD in the following domains: memory, orientation, language, praxis and constructive capacity. The total score in the Portuguese version of ADAS-Cog is composed of 11 subtests in the cognitive part and varies between 0 (better performance) and 68 points (worse performance), i.e., higher scores equals better performance.

    Baseline

  • Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)

    Evaluates the severity of cognitive deficits in AD in the following domains: memory, orientation, language, praxis and constructive capacity. The total score in the Portuguese version of ADAS-Cog is composed of 11 subtests in the cognitive part and varies between 0 (better performance) and 68 points (worse performance), i.e., higher scores equals better performance.

    12 weeks after the baseline

  • Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)

    Evaluates the severity of cognitive deficits in AD in the following domains: memory, orientation, language, praxis and constructive capacity. The total score in the Portuguese version of ADAS-Cog is composed of 11 subtests in the cognitive part and varies between 0 (better performance) and 68 points (worse performance), i.e., higher scores equals better performance.

    24 weeks after the baseline

  • Memory function evaluated through Memory Alteration Test (MAT)

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

    Baseline

  • Change in memory function evaluated through Memory Alteration Test (MAT)

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

    12 weeks after the baseline

  • Change in memory function evaluated through Memory Alteration Test (MAT)

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

    24 weeks after the baseline

  • Executive functions assessed through Frontal Assessment Battery (FAB)

    FAB assesses executive functions such as abstract thinking, mental flexibility, motor programming, interference sensibility, inhibitory control and environmental independence. Scores range between 0 - 18 points with higher scores indicating better cognitive function.

    Baseline

  • Change in executive functions assessed through Frontal Assessment Battery (FAB)

    FAB assesses executive functions such as abstract thinking, mental flexibility, motor programming, interference sensibility, inhibitory control and environmental independence. Scores range between 0 - 18 points with higher scores indicating better cognitive function.

    12 weeks after the baseline

  • Change in executive functions assessed through Frontal Assessment Battery (FAB)

    FAB assesses executive functions such as abstract thinking, mental flexibility, motor programming, interference sensibility, inhibitory control and environmental independence. Scores range between 0 - 18 points with higher scores indicating better cognitive function.

    24 weeks after the baseline

Secondary Outcomes (9)

  • Mood assessed through the Geriatric Depression Scale-15 (GDS-15)

    Baseline

  • Change in mood assessed through the GDS-15

    12 weeks after the baseline

  • Change in mood assessed through the GDS-15

    24 weeks after the baseline

  • Anxiety symptomatology assessed through the Geriatric Anxiety Inventory (GAI)

    Baseline

  • Change in anxiety symptomatology assessed through the GAI

    12 weeks after the baseline

  • +4 more secondary outcomes

Other Outcomes (2)

  • Sociodemographic, geographical and social information collected through the Sociodemographic, Geographical and Social Characteristics Questionnaire

    Baseline

  • Adherence to the intervention and dropouts evaluated through a session form

    up to 12 weeks after baseline

Study Arms (3)

Intervention group 1

EXPERIMENTAL

Participants in the intervention group 1 will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same program in every participant site.

Behavioral: Digital intervention

Intervention group 2

EXPERIMENTAL

Participants in the intervention group 2 will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same program in every participant site.

Behavioral: Physical/Analogue Intervention

Control group (No intervention)

NO INTERVENTION

Participants in the control group will receive treatment as usual (TAU) at the site, following the activities specified in their individual care plans.

Interventions

Individual cognitive stimulation sessions will be delivered using RehaCom software, which provides adaptive, computerised exercises targeting specific cognitive domains.

Intervention group 1

Individual cognitive stimulation sessions will employ structured physical materials, specifically the 'Memories from North to South©' and 'Cognitive Domains' resources, applied on an alternating basis.

Intervention group 2

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Age 65 or older.
  • Receive care/support services for at least three months.
  • A diagnosis of probable AD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision.
  • Preserved communication skills.
  • Native Portuguese speaker.
  • Total scores between 10 and 26 points on the Mini Mental State Examination.

You may not qualify if:

  • Cannot read and write.
  • Significant sensory or physical limitations.
  • Acute or chronic illness preventing participation.
  • Severe communication impairment.
  • Aggressive or disruptive behaviour.
  • Recent initiation (within two months) of neuroleptics, antipsychotics, or other psychoactive medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (39)

AMITEI

Leiria, Leria, Portugal

Location

Associação de Desenvolvimento Comunitário do Funchal - Garouta do Calhau

Funchal, Madeira, Portugal

Location

Instituto S. João de Deus Funchal

Funchal, Madeira, Portugal

Location

Associação Alzheimer Açores

Açores, Portugal

Location

Santa Casa da Misericórdia da Horta

Açores, Portugal

Location

Santa Casa da Misericórdia de Vila do Porto

Açores, Portugal

Location

CASTIIS

Aveiro, Portugal

Location

CEDIARA - Associação de Solidariedade Social de Ribeira de Fráguas

Aveiro, Portugal

Location

Centro Apoio Social Mozelos

Aveiro, Portugal

Location

Centro Social da Freguesia de Casal Comba

Aveiro, Portugal

Location

O Jardim - Centro de Solidariedade Social de Canedo

Aveiro, Portugal

Location

Santa Casa da Misericórdia de Espinho

Aveiro, Portugal

Location

Santa Casa da Misericórdia de Ovar

Aveiro, Portugal

Location

Patronato de Santo António - Lar D. José do Patrocínio Dias

Beja, Portugal

Location

Santa Casa da Misericórdia de Ferreira do Alentejo

Beja, Portugal

Location

Centro Social do Vale do Homem Casa da Alegria

Braga, Portugal

Location

Santa Casa da Misericórdia de Mirandela

Bragança, Portugal

Location

Residência Sénior DON ANTÓNIO - Hilário & Pereira

Castelo Branco, Portugal

Location

Santa Casa da Misericórdia da Soalheira

Castelo Branco, Portugal

Location

Santa Casa da Misericórdia de Vila Velha de Rodão

Castelo Branco, Portugal

Location

Associação Cultural Recreativa e Social de Samuel

Coimbra, Portugal

Location

Santa Casa da Misericórdia de Montemor-o-Novo

Evora, Portugal

Location

Santa Casa da Misericórdia de Vila Real de Santo António

Faro, Portugal

Location

Fundação João Bento Raimundo

Guarda, Portugal

Location

Santa Casa da Misericórdia de Figueira de Castelo Rodrigo

Guarda, Portugal

Location

Santa Casa da Misericórdia de Alcobaça

Leiria, Portugal

Location

Santa Casa da Misericórdia de Alvaiázere

Leiria, Portugal

Location

Santa Casa da Misericórdia de Alvorge

Leiria, Portugal

Location

Associação Casapiana de Solidariedade

Lisbon, Portugal

Location

Associação de Socorros da Freguesia de Turcifal

Lisbon, Portugal

Location

Centro Social Paroquial de Moita dos Ferreiros

Lisbon, Portugal

Location

Santa Casa da Misericórdia de Lisboa - Espaço ComVida

Lisbon, Portugal

Location

Santa Casa da Misericórdia de Campo Maior

Portalegre, Portugal

Location

Santa Casa da Misericórdia de Gaia - ERPI José Tavares Bastos

Porto, Portugal

Location

Quinta de Santa Ana RS

Viana do Castelo, Portugal

Location

Santa Casa da Misericórdia de Caminha

Viana do Castelo, Portugal

Location

Santa Casa da Misericórdia de Ponte de Lima

Viana do Castelo, Portugal

Location

Associação de Solidariedade Social do Alto Paiva

Viseu, Portugal

Location

Associação de Solidariedade Social e Recreativa de Nespereira

Viseu, Portugal

Location

MeSH Terms

Conditions

DementiaNeurocognitive DisordersCognitive DysfunctionDepressionAnxiety DisordersAlzheimer Disease

Interventions

Restraint, Physical

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesMental DisordersCognition DisordersBehavioral SymptomsBehaviorTauopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Behavior ControlTherapeuticsImmobilizationInvestigative Techniques

Study Officials

  • Susana I. Justo Henriques, PhD

    Polytechnic University of Beja

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2025

First Posted

June 27, 2025

Study Start

September 1, 2025

Primary Completion

September 13, 2025

Study Completion

March 13, 2026

Last Updated

March 25, 2026

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations